Compare · ATRC vs RMD
ATRC vs RMD
Side-by-side comparison of AtriCure Inc. (ATRC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.44B, about 20.7x ATRC ($1.37B).
- Over the past year, ATRC is down 20.7% and RMD is down 21.9% - ATRC leads by 1.3 points.
- ATRC has been more active in the news (13 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- ResMed Inc.
- Price
- $27.09-0.66%
- $196.01+0.92%
- Market cap
- $1.37B
- $28.44B
- 1M return
- -3.15%
- -6.57%
- 1Y return
- -20.67%
- -21.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- News (4w)
- 13
- 6
- Recent ratings
- 14
- 25
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ATRC
- SEC Form SD filed by AtriCure Inc.
- AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
- Director Prange Karen sold $85,950 worth of shares (3,000 units at $28.65), decreasing direct ownership by 10% to 26,373 units (SEC Form 4)
- Director Prange Karen was granted 6,144 shares, increasing direct ownership by 26% to 29,373 units (SEC Form 4)
- Director Telman Deborah H was granted 6,144 shares, increasing direct ownership by 28% to 28,328 units (SEC Form 4)
- Director Yuen Maggie was granted 6,144 shares, increasing direct ownership by 54% to 17,515 units (SEC Form 4)
- Director Johnson B Kristine was granted 6,144 shares, increasing direct ownership by 12% to 55,954 units (SEC Form 4)
- Director Nachman Shlomo was granted 6,144 shares, increasing direct ownership by 33% to 24,655 units (SEC Form 4)
- Director Groves Regina E was granted 6,144 shares, increasing direct ownership by 18% to 39,859 units (SEC Form 4)
- Director Wehrwein Sven was granted 6,144 shares, increasing direct ownership by 18% to 40,518 units (SEC Form 4)
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.